author-photo

S P Choo

20

Papers

669

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey

2021
Show All
- Source
- Cite
- Save
Citations (1)
Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit.

2021
Show All
- Source
- Cite
- Save
Citations (0)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

2021
Show All
- Source
- Cite
- Save
Citations (0)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (39)
O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (22)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (331)
430PPhase I study: Safety and tolerability of varlitinib (VAR) in combination with oxaliplatin and capecitabine (COX) or oxaliplatin and 5-FU (FOL) in advanced solid tumours

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Nivolumab in sorafenib-naive and - experienced patients with advanced hepatocellular carcinoma (HCC): checkMate 040 study

2017
Show All
- Source
- Cite
- Save
Citations (6)
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (31)